Low risk, double-digit earnings growth: Fisher & Paykel Healthcare
Add us as a preferred Google source
Portfolio stalwart, Fisher and Paykel Healthcare (ASX:FPH), continues to deliver for investors after announcing another typically strong full-year profit result, up 27% on the prior year. We have long been attracted to FPH’s global growth strategy and were not disappointed as both of the company’s major product groups, hospital/respiratory and acute care and homecare/obstructive sleep apnoea again delivered double-digit revenue and profit growth. We have reduced our weighting slightly on the back of the strong share price appreciation but continue to hold the stock as a core portfolio position given our forecast of relatively low risk, double-digit earnings growth over the medium term. (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Robert was appointed Head of Investments in 2009 and has been a Portfolio Manager since joining OC Funds Management in 2001. Robert is also an Executive Director of parent company, Copia Investment Partners.
3 topics
1 stock mentioned
Robert was appointed Head of Investments in 2009 and has been a Portfolio Manager since joining OC Funds Management in 2001. Robert is also an Executive Director of parent company, Copia Investment Partners.
Expertise
Robert was appointed Head of Investments in 2009 and has been a Portfolio Manager since joining OC Funds Management in 2001. Robert is also an Executive Director of parent company, Copia Investment Partners.
Expertise
Comments
Comments
Sign In or Join Free to comment
